Geoffrey Hamilton-Fairley is Vice Chairman of Oncimmune plc a company pioneering tests to measure the immune response to cancer in order to enable early cancer detection and to aid therapeutics. Over the past fourteen years Geoffrey has guided Oncimmune from a Nottingham University start-up through to a public company.  Establishing a proprietary operation in the US and distribution and partnerships worldwide including China, Geoffrey has co-ordinated worldwide with regulatory authorities and senior Key Opinion Leaders in order to accelerate clinical adoption. Geoffrey’s entrepreneurial career started by founding a number of companies in emerging technologies as well as media, broadcast, finance and property. His family connections to medicine are strong and he enjoys combining his own scientific background together with his diverse operational and financial experience to enable burgeoning science to become a reality. A particular sphere of interest being heath economics, Geoffrey headed the analysis enabling the test to be commercially successful and co-authored related academic publications as well as publications relating to the core science. Geoffrey has been instrumental in bringing about the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of over 12,000 high-risk smokers in Scotland.